WO2002045743A3 - Hcv vaccines - Google Patents

Hcv vaccines Download PDF

Info

Publication number
WO2002045743A3
WO2002045743A3 PCT/GB2001/005421 GB0105421W WO0245743A3 WO 2002045743 A3 WO2002045743 A3 WO 2002045743A3 GB 0105421 W GB0105421 W GB 0105421W WO 0245743 A3 WO0245743 A3 WO 0245743A3
Authority
WO
WIPO (PCT)
Prior art keywords
hvr
lymphocytes
different
hcv
peptides
Prior art date
Application number
PCT/GB2001/005421
Other languages
French (fr)
Other versions
WO2002045743A2 (en
Inventor
Jean-Pierre Allain
Chengyao Li
Enza Piccolella
Original Assignee
Univ Cambridge Tech
Univ Roma
Jean-Pierre Allain
Chengyao Li
Enza Piccolella
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030102A external-priority patent/GB0030102D0/en
Priority claimed from GB0030789A external-priority patent/GB0030789D0/en
Application filed by Univ Cambridge Tech, Univ Roma, Jean-Pierre Allain, Chengyao Li, Enza Piccolella filed Critical Univ Cambridge Tech
Priority to AU2002222139A priority Critical patent/AU2002222139A1/en
Publication of WO2002045743A2 publication Critical patent/WO2002045743A2/en
Publication of WO2002045743A3 publication Critical patent/WO2002045743A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

HCV vaccines are described which are capable of raising antibodies and/or helper T lymphocytes and/or cytotoxic T lymphocytes which are cross-reactive to the hypervariable 1 (HVR 1) region of the envelope protein E2 of different HCV strains. A preferred therapeutic vaccine for treatment of chronic HCV infection comprises a plurality of different groups of peptides, each peptide comprising a different known HVR 1 C-terminal sequence or a different consensus of known HVR 1 C-terminal sequences. The different groups of peptides are sequentially administered (preferably at intervals of 15-21 days) to raise antibodies, helper t lymphocytes, and cytotoxic T lymphocytes which are cross-reactive to the HVR 1 region(s) of the chronically infecting HCV strain(s). methods of selecting peptides for use in such vaccines are also described.
PCT/GB2001/005421 2000-12-09 2001-12-07 Hcv vaccines WO2002045743A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002222139A AU2002222139A1 (en) 2000-12-09 2001-12-07 Hcv vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0030102.8 2000-12-09
GB0030102A GB0030102D0 (en) 2000-12-09 2000-12-09 HCV vaccines
GB0030789.2 2000-12-18
GB0030789A GB0030789D0 (en) 2000-12-18 2000-12-18 HCV vaccines

Publications (2)

Publication Number Publication Date
WO2002045743A2 WO2002045743A2 (en) 2002-06-13
WO2002045743A3 true WO2002045743A3 (en) 2004-01-08

Family

ID=26245410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005421 WO2002045743A2 (en) 2000-12-09 2001-12-07 Hcv vaccines

Country Status (2)

Country Link
AU (1) AU2002222139A1 (en)
WO (1) WO2002045743A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
BR112015003326A2 (en) * 2012-08-16 2017-07-04 Ipierian Inc methods of treatment of a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (en) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド Tau peptides, anti-tau antibodies, and methods for their use
WO2023082022A1 (en) * 2021-11-11 2023-05-19 University Health Network Polyvalent vaccines and methods for making them

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060132A1 (en) * 1998-05-19 1999-11-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060132A1 (en) * 1998-05-19 1999-11-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DEL PORTO PAOLA ET AL: "High prevalence of hypervariable region 1-specific and -cross-reactive CD4+ T cells in HCV-infected individuals responsive to IFN-alpha treatment.", VIROLOGY, vol. 269, no. 2, 10 April 2000 (2000-04-10), pages 313 - 324, XP002228435, ISSN: 0042-6822 *
LI CHENGYAO ET AL: "Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1.", JOURNAL OF VIROLOGY, vol. 75, no. 24, December 2001 (2001-12-01), December, 2001, pages 12412 - 12420, XP002228438, ISSN: 0022-538X *
PUNTORIETO G ET AL: "Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 13, 1 July 1998 (1998-07-01), pages 3521 - 3533, XP002111268, ISSN: 0261-4189 *
SHANG DAZHUANG ET AL: "Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits.", VIROLOGY, vol. 258, no. 2, 5 June 1999 (1999-06-05), pages 396 - 405, XP002228433, ISSN: 0042-6822 *
WATANABE KAZUO ET AL: "The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence.", VIROLOGY, vol. 264, no. 1, 10 November 1999 (1999-11-10), pages 153 - 158, XP002228436, ISSN: 0042-6822 *
ZHAI W ET AL: "Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries.", JOURNAL OF VIRAL HEPATITIS. ENGLAND MAR 1999, vol. 6, no. 2, March 1999 (1999-03-01), pages 115 - 124, XP002228437, ISSN: 1352-0504 *
ZHOU YI-HUA ET AL: "Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus.", VIROLOGY, vol. 256, no. 2, 10 April 1999 (1999-04-10), pages 360 - 370, XP002228434, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
WO2002045743A2 (en) 2002-06-13
AU2002222139A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
Matsuo et al. Establishment of a foreign antigen secretion system in mycobacteria
EP2269640A2 (en) Hcv vaccine compositions
ES2199932T3 (en) RECOMBINANT POXVIRUS AND STREPTOCOCIC VACCINE CONTAINING PROTEIN M.
DE60043856D1 (en) IMPROVEMENTS IN OR RELATED TO IMMUNE RESOLUTIONS AGAINST HIV
NO20025153D0 (en) Methods and Compositions to Impair the Reproduction of HIV-1
CN101421299A (en) Peptide vaccine for inducing production of anti-amyloid- -peptide antibody
RU2002103604A (en) Antigenic Meningococcal Peptides
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
Layton et al. Induction of single and dual cytotoxic T‐lymphocyte responses to viral proteins in mice using recombinant hybrid Ty–virus‐like particles
Yang et al. Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice
HUP9801266A2 (en) Multimeric, recombinant urease vaccine
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
WO2002045743A3 (en) Hcv vaccines
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
ATE248601T1 (en) VACCINE AGAINST ROTAVIRUS INFECTIONS CONTAINING PEPTIDES OF THE VIRAL TEROTOXIN NSP4
CN101717433A (en) Polypeptide immunogen, preparation method and application thereof
CN100410276C (en) Polypeptide
LOLEIT et al. Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus
CA2344173C (en) Immunogenic liposome compositions
DE69433057D1 (en) PEPTIDES FOR USE IN VACCINATING AND INDUCING NEUTRALIZING ANTIBODIES AGAINST THE HUMAN IMMUNE VIRUS
WO1999009177A3 (en) Papilloma virus, agents for the detection thereof and for the therapy of the diseases caused by said virus
O’Donovan et al. A vector expressing feline mature IL-18 fused to IL-1β antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus
US20090220517A1 (en) Method for producing epitomers and their uses on carrier microorganisms
CA2431881A1 (en) Polypeptide inducing hiv-neutralising antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP